SCHEMBL7937565

SCHEMBL7937565

Cc1ccc(S(=O)(=O)Oc2cc(C(=O)O)cc(O)c2O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.51
GAA P10253 4/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
ESR1 P03372 1/20 0.51
ESR2 Q92731 1/20 0.51
MAPT P10636 3/20 0.46
ALDH1A1 P00352 2/20 0.46
POLB P06746 1/20 0.45
POLA1 P09884 1/20 0.45
ANTXR2 P58335 1/20 0.45
SNCA P37840 2/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9053528 0.89 CYP1A2 (0.50) GAAKMT2AMEN1ESR1ESR2
SCHEMBL9053651 0.87 KMT2A (0.50) GAAKMT2AMEN1ESR1ESR2
SCHEMBL9054334 0.87 PTGS2 (0.51) PTGS2GAAMAPTALDH1A1POLB
SCHEMBL7632373 0.86 GAA (0.53) GAAKMT2AMEN1ESR1ESR2
SCHEMBL9052978 0.86 PTGS2 (0.47) PTGS2KMT2AMEN1MAPTALDH1A1
SCHEMBL9054847 0.86 HTT (0.54) GAAKMT2AMEN1ESR1ESR2
SCHEMBL9054697 0.85 KMT2A (0.47) GAAKMT2AMEN1ESR1ESR2
SCHEMBL9059038 0.85 KMT2A (0.48) GAAKMT2AMEN1ESR1ESR2
SCHEMBL9052909 0.85 SNCA (0.49) GAAKMT2AMEN1ESR1ESR2
SCHEMBL9054965 0.85 PTGS2 (0.48) PTGS2GAAKMT2AMEN1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0888292-B1 TRICYCLIC COMPOUNDS HAVING ACTIVITY SPECIFIC FOR INTEGRINS, PARTICULARLY ALPHAvBETA3 INTEGRINS, METHOD FOR PREPARING SAME, INTERMEDIATES THEREFOR, USE OF SAID COMPOUNDS AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA SA (FR) 2001-10-31 EP disclosed
EP-0729933-B1 Tricyclic derivatives, their preparation, their use in the preparation of optically active or racemic colchicine, thiocolchicine and analogues or derivatives, and intermediates HOECHST MARION ROUSSEL INC (FR) 2000-01-26 EP disclosed
EP-0888292-A1 TRICYCLIC COMPOUNDS HAVING ACTIVITY SPECIFIC FOR INTEGRINS, PARTICULARLY $g(a)v$g(b)3 INTEGRINS, METHOD FOR PREPARING SAME, INTERMEDIATES THEREFOR, USE OF SAID COMPOUNDS AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME HOECHST MARION ROUSSEL (FR) 1999-01-07 EP disclosed
WO-1997034865-A1 TRICYCLIC COMPOUNDS HAVING ACTIVITY SPECIFIC FOR INTEGRINS, PARTICULARLY αvβ3 INTEGRINS, METHOD FOR PREPARING SAME, INTERMEDIATES THEREFOR, USE OF SAID COMPOUNDS AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME HOECHST MARION ROUSSEL (FR) 1997-09-25 WO disclosed
EP-0729933-A1 Tricyclic derivatives, their preparation, their use in the preparation of optically active or racemic colchicine, thiocolchicine and analogues or derivatives, and intermediates ROUSSEL-UCLAF (FR) 1996-09-04 EP disclosed
WO-1996008483-A1 GALLIC ACID DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS ROUSSEL UCLAF (FR) 1996-03-21 WO disclosed
EP-0491600-A1 Process for the regiospecific monofunctionalisation of a phenolic hydroxy group of a polyphenol ROUSSEL UCLAF (FR) 1992-06-24 EP disclosed